Combined thrombectomy and intracoronary administration of glycoprotein IIb/IIIa inhibitors improves myocardial reperfusion in patients undergoing primary percutaneous coronary intervention: a meta-analysis

被引:6
|
作者
Niu, Xiao-Wei [1 ]
Zhang, Jing-Jing [2 ]
Bai, Ming [3 ]
Peng, Yu [3 ]
Zhang, Zheng [3 ]
机构
[1] Lanzhou Univ, Clin Med Sch 1, Lanzhou, Gansu, Peoples R China
[2] Baiyin Second Peoples Hosp, Baiyin, Peoples R China
[3] Lanzhou Univ, Dept Cardiol, Hosp 1, 1 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China
关键词
Glycoprotein IIb/IIIa inhibitors; Meta-analysis; Myocardial reperfusion; Thrombectomy; Percutaneous coronary intervention; MANUAL THROMBUS ASPIRATION; PRIMARY ANGIOPLASTY; COMBINATION TREATMENT; INFARCTION; ABCIXIMAB; TIROFIBAN; PERFUSION; IMPACT; EPTIFIBATIDE; MORTALITY;
D O I
10.11909/j.issn.1671-5411.2017.10.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Suboptimal myocardial reperfusion is common in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Furthermore, it results in increased infarct size and mortality rates. We performed a meta-analysis to evaluate the role of aspiration thrombectomy (AT) combined with intracoronary administration of glycoprotein IIb/IIIa inhibitors (GPI) in the improvement of myocardial reperfusion and clinical outcomes. Methods PubMed, Embase, Web of Science, and CENTRAL databases were searched for randomized controlled trials (RCTs) investigating combined AT and intracoronary GPI treatment versus AT alone. Outcomes of interest were thrombolysis in myocardial infarction myocardial perfusion grade (TMPG), infarct size (IS) assessed by cardiac magnetic resonance imaging, left ventricular ejection fraction (LVEF), major adverse cardiac events (MACE) at short-term (<= 1 month) and long-term (6. 12 months) follow-up, and bleeding complications during the hospital stay. Results Eight trials involving 923 patients were included. Compared with AT alone, combined AT and intracoronary GPI significantly increased TMPG 3 flow (RR: 1.15, 95% CI: 1.04 to 1.26), reduced IS [mean difference (MD): -3.46, 95% CI: -5.18 to -1.73], and improved LVEF (MD: 1.44, 95% CI: 0.54 to 2.33). Furthermore, GPI use decreased the risk of MACE at long-term follow-up (RR: 0.60, 95% CI: 0.37 to 0.98). There was no significant difference between the two groups in the incidence of minor and major bleeding complications. Conclusions Our findings showed that compared with AT alone, combined AT and intracoronary GPI treatment resulted in improved myocardial reperfusion, better cardiac function, and MACE-free survival benefits at the long-term follow-up for patients with STEMI undergoing PPCI.
引用
收藏
页码:614 / 623
页数:10
相关论文
共 50 条
  • [11] Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention
    McCollam, PL
    Foster, DA
    Riesmeyer, JS
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (12) : 1251 - 1256
  • [12] Intracoronary versus intravenous glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in patients with STEMI: a systematic review and meta-analysis
    JongSung Hahn
    Jinyoung Jeon
    Min Jung Geum
    Hyun Woo Lee
    Jaekyu Shin
    Woo-Young Chung
    Yun Mi Yu
    Young-Mi Ah
    Thrombosis Journal, 21
  • [13] Long-term outcomes with aspiration thrombectomy for patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials
    Elgendy, Akram Y.
    Elgendy, Islam Y.
    Mahmoud, Ahmed N.
    Bavry, Anthony A.
    CLINICAL CARDIOLOGY, 2017, 40 (08) : 534 - 541
  • [14] Meta-Analysis of Randomized Controlled Trials of Intracoronary Versus Intravenous Administration of Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention for Acute Coronary Syndrome
    Friedland, Sayuri
    Eisenberg, Mark J.
    Shimony, Avi
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (09) : 1244 - 1251
  • [15] Current role of glycoprotein IIb/IIIa receptor inhibitors in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention after pretreatment with loading dose thienopyridines
    Dong, Lili
    Wang, Yongshi
    Wu, Boting
    Shu, Xianhong
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 167 (02) : 608 - 613
  • [16] Glycoprotein IIb/IIIa Inhibitors in Patients With Renal Insufficiency Undergoing Percutaneous Coronary Intervention
    Anderson, Joe R.
    Riding, Dan
    CARDIOLOGY IN REVIEW, 2008, 16 (04) : 213 - 218
  • [17] A Comparison of Abciximab and Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Primary Percutaneous Coronary Intervention A Meta-Analysis of Contemporary Randomized Controlled Trials
    Gurm, Hitinder S.
    Tamhane, Umesh
    Meier, Pascal
    Grossman, P. Michael
    Chetcuti, Stanley
    Bates, Eric R.
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (03) : 230 - 236
  • [18] Comparison of myocardial reperfusion between intracoronary versus intravenous cangrelor administration in patients undergoing primary percutaneous coronary intervention
    Muraca, Iacopo
    Pennesi, Matteo
    Mattesini, Alessio
    Migliorini, Angela
    Carrabba, Nazario
    Virgili, Giacomo
    Bruscoli, Filippo
    Demola, Pierluigi
    Colombi, Riccardo
    Pontecorboli, Giulia
    Marchionni, Niccolo
    Di Mario, Carlo
    Valenti, Renato
    CARDIOLOGY JOURNAL, 2023, 30 (04) : 587 - 594
  • [19] Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: A meta-analysis of randomized trials
    Sciahbasi, Alessandro
    Biondi-Zoccai, Giuseppe
    Romagnoli, Enrico
    Valgimigli, Marco
    Rasoul, Saman
    van't Hof, Arnoud
    Lioy, Ernesto
    Stone, Gregg W.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2012, 155 (02) : 243 - 248
  • [20] Early Administration of Small-Molecule Glycoprotein IIb/IIIa Inhibitors Before Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Insights From Randomized Clinical Trials
    Dong, Lili
    Zhang, Feng
    Shu, Xianhong
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2010, 15 (02) : 135 - 144